SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Novo Nordisk A/S: Degludecplus Provides Superior Glycaemic Control Compared to Insulin Glargine in a Phase 3a Trial in Japanese People with Type 2 Diabetes